FDA broadens approval for Exact's Cologuard

FDA approved colorectal cancer screening test Cologuard from Exact Sciences Corp. (NASDAQ:EXAS) for average-risk adults ages 45 and older. The non-invasive home-based stool test was marketed for aver...